You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Developing a Diagnostic Blood Test for Sarcoidosis

    SBC: Sarcoidosis Diagnostic Testing LLC            Topic: NHLBI

    DESCRIPTION provided by applicant SARCOIDOSIS DIAGNOSTIC TESTING LLC is a medical diagnostics company developing a diagnostic blood test for sarcoidosis Sarcoidosis is a multisystem granulomatous disorder that affects per people per year in the U S and disproportionately affects African Americans and women Sarcoidosis can lead to advanced pulmonary fibrosis pulmonary hyperte ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Vulnerable Plaque Amplified Optical Analyzer

    SBC: Energy Research Company            Topic: NHLBI

    DESCRIPTION provided by applicant Energy Research Company ERCo in a collaboration with The City College of New York CCNY and Columbia University Medical Center CUMC proposes developing the Vulnerable Plaque Amplified Optical Analyzer VPAOA a fiber optic catheter instrument based on patented amplified spectroscopy technology for detecting and analyzing vulnerable plaque VP in corona ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. A Low Cost, Quantitative, Chemical Specific Device for Illicit Drug Detection

    SBC: MKS Technology            Topic: NIDA

    DESCRIPTION provided by applicant This proposal will assess the quantitative capabilities of surface enhanced Raman scattering SERS detection of cocaine and marijuana metabolites in urine samples Combining low cost instrumentation and novel chemical sensing provides an innovative new approach for diagnosing illicit drug use Current methods use a colorimetric indicator to screen specimens fo ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Interactive technology for media literacy drug prevention in community groups

    SBC: Real Prevention LLC            Topic: R41

    DESCRIPTION provided by applicant The goal of this STTR R proposal is to transfer the technology from Rutgers University to REAL Prevention needed to adapt a substance use prevention media literacy curriculum for web based delivery in community organizations for commercialization Substance use increases in frequency and risk through mid adolescence yet most prevention interventions target ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Treatment of Acute Radiation Syndrome using PIF, a Natural Immune Modulator

    SBC: BioIncept, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Recent nuclear accidents and threats have highlighted the growing risk of widespread radiation exposure causing a potentially devastating public health emergency Acute radiation syndrome ARS develops after total body or partial body irradiation at a moderate to high dose and is especially damaging to the immune system Damage to the skin gut and central n ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne muscular dystrophy is caused by mutations in the dystrophin gene resulting in the loss of the dystrophin glycoprotein complex in skeletal muscle Loss of dystrophin results in reduced sarcolemmal integrity progressive muscle damage and compromised muscle function There is currently no cure and limited treatment options for DMD and all affected child ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Use of EF2K inhibitors to inhibit tumor growth and sensitize cancer cells to existing chemotherapy treatment

    SBC: LONGEVICA PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Eukaryotic elongation factor protein kinase eEF K is a ubiquitously expressed protein that belongs to a family of alpha kinases characterized by an andquot atypicalandquot kinase domain Our recent findings demonstrate that inhibition or genetic inactivation of eEF K protects normal tissues from cytotoxic effects of ionizing radiation and chemotherapeutic ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government